Diamedica Therapeutics Inc (DMAC)
R&D Expense Growth
29.16%
Fiscal year · Period ending:
DMAC R&D Expense Growth
Latest reported29.16%period ending
Latest reported29.16%period ending
DMAC FY R&D Growth (YoY) (0.00% → 29.16%)
Latest values, visible window
High-resolution chart · PNG
DMAC r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 29.1599% | |
| 45.3623% | |
| 67.2407% | |
| -10.5647% | |
| 6.8251% | |
| 3.8608% | |
| 74.7015% | |
| 41.048% | |
| 81.8063% | |
| 99.0146% | |
| -76.1329% | |
| -1.8082% | |
| -27.3995% | |
| 123.8367% | |
| 189.3854% | |
| -41.1241% | |
| 31.3123% | |
| -2.5532% | |
| 72.8902% | |
| 2,613.0983% | |
| -95.0755% | |
| 0% |